Junshi biosciences

Index
Globenewswire

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Globenewswire

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

Globenewswire

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Globenewswire

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Globenewswire

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Globenewswire

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

Globenewswire

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

Globenewswire

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Globenewswire

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

Globenewswire

Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

Globenewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer

Globenewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Globenewswire

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer